• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Gilead Sciences Inc.

    5/14/26 5:11:39 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email
    FWP 1 tm2531124d3_fwp.htm FWP

     

    Free Writing Prospectus

    Filed Pursuant to Rule 433

    Registration Statement No. 333-273745

    May 14, 2026

     

    GILEAD SCIENCES, INC.

     

     

    PRICING TERM SHEET

    4.250% SENIOR NOTES DUE 2028

    4.400% SENIOR NOTES DUE 2029

    4.600% SENIOR NOTES DUE 2031

    4.900% SENIOR NOTES DUE 2034

     

    Issuer:  

    Gilead Sciences, Inc. (the “Company”)

     

    Title of Security:

    4.250% Senior Notes due 2028 (the “2028 Notes”)

    4.400% Senior Notes due 2029 (the “2029 Notes”)

    4.600% Senior Notes due 2031 (the “2031 Notes”)

    4.900% Senior Notes due 2034 (the “2034 Notes”)

     

    Principal Amount:

    2028 Notes: $500,000,000

    2029 Notes: $1,000,000,000

    2031 Notes: $1,000,000,000

    2034 Notes: $500,000,000

     

    Trade Date:

    May 14, 2026

     

    Settlement Date:            

    May 20, 2026 (T+4)

     

    It is expected that delivery of the notes will be made against payment therefor on or about May 20, 2026, which is the fourth business day following the date of the pricing of the notes (T+4). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day unless the parties to that trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on or after the date of pricing but prior to the closing date may be required, by virtue of the fact that the notes initially will settle in T+4, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement and should consult their own advisers.

     

     

     

    Maturity Date:

    2028 Notes: May 20, 2028

    2029 Notes: May 20, 2029

    2031 Notes: May 20, 2031

    2034 Notes: May 20, 2034

     

    Price to Public:

     

    2028 Notes: 99.958% of the principal amount

    2029 Notes: 99.981% of the principal amount

    2031 Notes: 99.996% of the principal amount

    2034 Notes: 99.987% of the principal amount

     

    Yield to Maturity:

    2028 Notes: 4.272%

    2029 Notes: 4.407%

    2031 Notes: 4.601%

    2034 Notes: 4.902%

     

    Spread to Benchmark Treasury:

     

    2028 Notes: 28 basis points

    2029 Notes: 38 basis points

    2031 Notes: 48 basis points

    2034 Notes: 45 basis points

     

    Benchmark Treasury:

     

    2028 Notes: 3.750% due April 30, 2028

    2029 Notes: 3.875% due April 15, 2029

    2031 Notes: 3.875% due April 30, 2031

    2034 Notes: 4.125% due February 15, 2036

       
    Benchmark Treasury Price / Yield:

    2028 Notes: 99-17+ / 3.992%

    2029 Notes: 99-18 ⅝ / 4.027%

    2031 Notes: 98-29 / 4.121%

    2034 Notes: 97-13 ¾ / 4.452%

     

    Interest Payment Dates:  

     

    2028 Notes: May 20 and November 20, commencing November 20, 2026

    2029 Notes: May 20 and November 20, commencing November 20, 2026

    2031 Notes: May 20 and November 20, commencing November 20, 2026

    2034 Notes: May 20 and November 20, commencing November 20, 2026

       
    Optional Redemption:  

    Make-Whole Call:

     

    2028 Notes: T+5 basis points, prior to May 20, 2028

    2029 Notes: T+10 basis points, prior to April 20, 2029 (assuming the notes called for redemption matured on April 20, 2029)

    2031 Notes: T+10 basis points, prior to April 20, 2031 (assuming the notes called for redemption matured on April 20, 2031)

    2034 Notes: T+10 basis points, prior to March 20, 2034 (assuming the notes called for redemption matured on March 20, 2034)

     

     

     

    Par Call:

     

    2028 Notes: N/A (Make-Whole Call only)

    2029 Notes: At 100%, on or after April 20, 2029

    2031 Notes: At 100%, on or after April 20, 2031

    2034 Notes: At 100%, on or after March 20, 2034

     

    CUSIP / ISIN:

    2028 Notes: 375558 CJ0 / US375558CJ09

    2029 Notes: 375558 CK7 / US375558CK71

    2031 Notes: 375558 CL5 / US375558CL54

    2034 Notes: 375558 CM3 / US375558CM38

     

    Day Count Convention:

    360-day year consisting of twelve 30-day months

     

    Joint Book-Running Managers:

    Barclays Capital Inc.

    BofA Securities, Inc.

    Citigroup Global Markets Inc.

    Goldman Sachs & Co. LLC

    HSBC Securities (USA) Inc.

    J.P. Morgan Securities LLC

    Mizuho Securities USA LLC

    Morgan Stanley & Co. LLC

    RBC Capital Markets, LLC

    SG Americas Securities, LLC

    TD Securities (USA) LLC

    U.S. Bancorp Investments, Inc.

    Wells Fargo Securities, LLC

     

    Co-Managers:

    Blaylock Van, LLC

    CastleOak Securities, L.P.

    Independence Point Securities LLC

    Samuel A. Ramirez & Company, Inc.

    Siebert Williams Shank & Co., LLC

     

    *      *      *

     

    The issuer has filed a registration statement (including a prospectus) and a prospectus supplement with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the prospectus supplement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. toll-free at 1-888-603-5847, calling BofA Securities, Inc. toll free at 1-800-294-1322 or calling Citigroup Global Markets Inc. toll-free at 1-800-831-9146.

     

    This pricing term sheet supplements the Preliminary Prospectus Supplement filed by Gilead Sciences, Inc. on May 14, 2026 relating to its Prospectus dated August 4, 2023.

     

     

    Get the next $GILD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GILD

    DatePrice TargetRatingAnalyst
    7/21/2026$127.00Outperform → Market Perform
    Leerink Partners
    7/6/2026$155.00Hold → Buy
    HSBC Securities
    5/20/2026$165.00Hold → Buy
    Maxim Group
    3/10/2026$180.00Buy
    Jefferies
    2/20/2026$155.00Equal Weight
    Barclays
    2/11/2026$140.00 → $170.00Buy
    Needham
    1/7/2026$145.00Buy
    UBS
    11/24/2025$140.00Buy
    Truist
    More analyst ratings

    $GILD
    SEC Filings

    View All

    Gilead Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

    5/20/26 4:15:36 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Gilead Sciences Inc.

    424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)

    5/18/26 4:15:38 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Gilead Sciences Inc.

    144 - GILEAD SCIENCES, INC. (0000882095) (Subject)

    5/15/26 4:07:18 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug HEPCLUDEX (ORIG-1) with active ingredient BULEVIRTIDE-GMOD) has changed to 'Approval' on 05/22/2026. Application Category: BLA, Application Number: 761468, Application Classification:

    5/26/26 6:57:56 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)

    5/21/26 4:17:16 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Labeling

    5/21/26 9:34:58 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    7/16/26 6:08:03 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    7/16/26 4:54:41 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    7/2/26 4:14:19 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

    – Trodelvy is a New Backbone Therapy and the Only Approved ADC in First-Line mTNBC Across PD-L1 Status – – Approval Builds on Trodelvy’s Leadership in Second-Line mTNBC and Pre-Treated HR+/HER2- Metastatic Breast Cancer with More than 75,000 Patients Treated Globally – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy is now approved in first-line mTNBC either as a single agent fo

    6/24/26 4:29:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

    AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase ("PARP") inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity.

    6/24/26 8:30:00 AM ET
    $MRK
    $PFE
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

    –Trodelvy is the First Antibody-Drug Conjugate (ADC) and First New Treatment Option in 20 Years in Europe for Certain Patients with First-Line Metastatic Triple-Negative Breast Cancer – – Authorization Based on ASCENT-03 Study in Which Trodelvy Demonstrated Highly Statistically Significant and Clinically Meaningful Progression-Free Survival (PFS) Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC

    6/23/26 7:45:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

    2/13/24 5:48:49 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gilead Sciences downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Gilead Sciences from Outperform to Market Perform and set a new price target of $127.00

    7/21/26 8:03:57 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Gilead Sciences from Hold to Buy and set a new price target of $155.00

    7/6/26 8:49:10 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences upgraded by Maxim Group with a new price target

    Maxim Group upgraded Gilead Sciences from Hold to Buy and set a new price target of $165.00

    5/20/26 8:22:14 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Financials

    Live finance-specific insights

    View All

    U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

    – Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials – Gilead Sciences, Inc. (NASDAQ:GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo® (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. "This filing reflects Gilead's continued commitment to advancing new HIV prevention options," said Dietmar Berger, Chief Medical Officer, Gilead Sciences. "Nea

    6/15/26 4:34:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Announces First Quarter Financial Results

    Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the first quarter 2026. "Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Building on the strongest pipeline in Gilead's history, we are adding potentially best-in-disease assets and platforms in oncolog

    5/7/26 4:01:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (NASDAQ:ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx's successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and elim

    4/28/26 8:45:00 AM ET
    $ACLX
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Leadership Updates

    Live Leadership Updates

    View All

    Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par

    12/18/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/9/24 6:21:28 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 3:32:27 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Gilead Sciences Inc.

    SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 2:49:26 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care